Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Wilson Therapeutics in connection with directed share issue
Mandate

Vinge advises Wilson Therapeutics in connection with directed share issue

December 12, 2017

Vinge has advised Wilson Therapeutics on a directed new issue of shares, whereby Wilson Therapeutics raises proceeds of approximately SEK 244 million, before issue costs.

The share issue is directed to a number of selected institutions and sector specialist funds, internationally and in Sweden, on the basis of an accelerated bookbuilding process.

Vinge’s team consisted of Christian Lindhé, Erik Sjöman, Mattias Sköld, Ludvig Frithiof and Astrid Karlsson.

Related

Vinge advises Irisity in connection with issue of units

 Vinge advises Irisity AB (publ) in connection with its rights issue of units consisting of shares and warrants. The issue is guaranteed to 80 per cent through subscription commitments and external guarantors.
October 03, 2024

Vinge has advised Egetis Therapeutics in connection with directed share issuances

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with directed share issuances whereby Egetis Therapeutics receives gross proceeds of SEK 300 million.
October 03, 2024

Vinge advises Orlando Capital V in connection with the acquisition of Swedpaper AB

 Vinge has acted as legal advisor to Orlando Capital V in connection with the acquisition of Swedpaper AB, a leading European manufacturer of white sack and kraft paper used in various packaging solutions for the retail, food and construction industries. Swedpaper AB's revenue for the fiscal year 2023 amounted to over EUR 68 million.
September 30, 2024